Drug Trial Radar · NCT01690052
Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva
Last checked: Nov 20, 2026Latest source record: Jun 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Jan 2009
Primary completion
Jun 2010
Study completion Jul 2010
Sponsor
- Lead sponsor
- University of KentuckyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 21, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objectives were: 1) To determine the efficacy of both cevimeline and pilocarpine in the secretion of saliva in patients with xerostomia, and 2) To compare the side-effects between the treatment for xerostomia with cevimeline and with pilocarpine.
Conditions
- Dry Mouth
Interventions
CevimelineDrug
Cevimlenine Vs Pilocarpine, cross over design. Two sequences were evaluated "cevimeline first, then pilocarpine" and "pilocarpine first, then cevimeline". Each sequence was evaluated for 4 weeks with one week "washout" period in between both sequences. 15 patients were randomly assigned to a specific sequence by a research pharmacist independent from the study authors. The patients received 30mg of cevimeline three times a day and pilocarpine 5mg three times a day.
PilocarpineDrug
Cevimlenine Vs Pilocarpine, cross over design, 4 weeks, one week wash out
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Saliva Production in ml.Time frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Kentucky Orofacial Pain Center College of Dentistry
Lexington, Kentucky
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.